Drugs / Recombinant Herpes Zoster Vaccine (CHO cells)
Recombinant Herpes Zoster Vaccine (CHO cells)
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05636436 | Dec 2022 → Dec 2024 overdue | herpes zoster | MAXVAX Biotechnology Limited Liability Company | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05856084 | May 2023 → Dec 2024 overdue | herpes zoster | MAXVAX Biotechnology Limited Liability Company | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Herpes Zoster Vaccine (CHO cells) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05856084 ↗ |
| Modality | Vaccine | “recombinant herpes zoster vaccine (CHO cells)” NCT05636436 ↗ |
| Route | Intramuscular | “administered intramuscularly (IM)” NCT05856084 ↗ |